Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
- Conditions
- DengueChikungunya
- Interventions
- Biological: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 900
- Registration Number
- NCT06973772
- Locations
- 🇧🇷
Centro Médico de São Francisco, Curitiba, PR, Brazil
🇧🇷Centro de Pesquisa Inova, Toledo, PR, Brazil
🇧🇷Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
- Conditions
- Dengue
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 997
- Registration Number
- NCT06891950
- Locations
- 🇧🇷
Centro de Pesquisa 1 (POA01): Hospital São Lucas - PUCRS, Porto Alegre, Rio Grande do Sul, Brazil
Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
- Conditions
- Avian Influenza A Virus
- Interventions
- Biological: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcgBiological: Monovalent influenza vaccine type A (H5N8) 15 mcgOther: Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 700
- Registration Number
- NCT06842173
- Locations
- 🇧🇷
Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Plátano Centro de Pesquisa Clínica LTDA, Recife, Pernambuco, Brazil
🇧🇷Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S), Serrana, São Paulo, Brazil
Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .
- Conditions
- Influenza, Human
- Interventions
- Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineageBiological: Quadrivalent Influenza Vaccine (split virion, inactivated)Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 1373
- Registration Number
- NCT05779020
- Locations
- 🇧🇷
Instituto Auto Imune de Pesquisa e Educação Continuada - Real Hospital Português de Beneficência em Pernambuco (Site REC01), Recife, Pernambuco, Brazil
🇧🇷Centro Oncológico de Roraima - CECOR (Site BVB-01), Boa Vista, Roraima, Brazil
🇧🇷Centro de Pesquisas Clínicas da Universidade Federal de Sergipe (Site AJU01), Laranjeiras, Sergipe, Brazil
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 1364
- Registration Number
- NCT05710224
- Locations
- 🇧🇷
Hospital Tacchini (Site 0006), Bento Gonçalves, Rio Grande Do Sul, Brazil
🇧🇷Fundação Universidade de Caxias do Sul (FUCS) - Instituto de Pesquisas em Saúde (IPS) (Site 0017), Caxias do Sul, Rio Grande Do Sul, Brazil
🇧🇷ONCOSITE - Centro de Pesquisa Clinica em Oncologia (Site 0005), Ijuí, Rio Grande Do Sul, Brazil
Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine
- Conditions
- HealthyCoronavirus Infections
- Interventions
- Biological: NDV-HXP-S 10μgBiological: BNT162b2 30μg
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 4400
- Registration Number
- NCT05354024
- Locations
- 🇧🇷
Instituto Aggeu Magalhães - Fundação Osvaldo Cruz - Pernambuco, Recife, Pernambuco, Brazil
🇧🇷Centro de Pesquisa Clínica S, Serrana, São Paulo, Brazil
🇧🇷Universidade Municipal de São Caetano do Sul, São Caetano Do Sul, São Paulo, Brazil
Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil
- Conditions
- HealthyCoronavirus Infections
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 320
- Registration Number
- NCT04993209
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine
- Conditions
- SARS-CoV-2 Acute Respiratory Disease
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 2549
- Registration Number
- NCT04845048
- Locations
- 🇧🇷
Centro de Saúde Escola da Faculdade de Medicina de Botucatu - Unesp., Botucatu, São Paulo, Brazil
🇧🇷Centro de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP) Dr. Joel Domingos Machado., Ribeirão Preto, São Paulo, Brazil
🇧🇷Centro de Referência de Imunobiológicos Especiais. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CRIEHCFMUSP), São Paulo, Brazil
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
- Conditions
- Diabetes MellitusCardiovascular DiseasesImmunosuppressionCancerOther Complication of Kidney TransplantChemotherapyRenal DiseaseChronic Obstructive Pulmonary DiseaseCOVID-19
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 618
- Registration Number
- NCT04834089
- Locations
- 🇧🇷
Hospital do Rim, Sao Paulo, SP, Brazil
🇧🇷Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine
- Conditions
- Covid19
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 27711
- Registration Number
- NCT04747821
- Locations
- 🇧🇷
Hospital Estadual de Serrana, Serrana, SP, Brazil